Nomad Power Solutions (NMAD) Common Equity (2010 - 2026)
Nomad Power Solutions (NMAD) posted Common Equity of $25.0 million for Q2 2026, up 127.96% on a QoQ basis from $11.0 million in Q4 2025, and up 3735.69% year-over-year from $651456.0 in Q2 2025.
Analysis
Nomad Power Solutions (NMAD) Common Equity (2010 - 2026) Analysis & Trends
Nomad Power Solutions has reported Common Equity for 17 years, with the latest figure at $25.0 million in Q2 2026.
- On a quarterly basis, Common Equity rose 3735.69% year-over-year to $25.0 million in Q2 2026; TTM through Jun 2026 was $25.0 million, a 3735.69% increase from a year earlier, with the FY2025 full-year figure at $11.0 million, up 1225.11% from the prior year.
- Common Equity was $25.0 million for Q2 2026 at Nomad Power Solutions, up from $11.0 million in the prior quarter.
- The five-year high for Common Equity was $25.0 million in Q2 2026, with the low at $651456.0 in Q2 2025.
- Average Common Equity over 5 years is $5.2 million, with a median of $4.0 million recorded in 2023.
- The sharpest annual moves came in 2024 and 2026: Common Equity slumped 79.29% in 2024, then jumped 3735.69% in 2026.
- Over 5 years, Common Equity stood at $5.2 million in 2022, then dropped by 22.66% to $4.0 million in 2023, then slumped by 79.29% to $827219.0 in 2024, then jumped by 1225.11% to $11.0 million in 2025, then jumped by 127.96% to $25.0 million in 2026.
- The last three Common Equity figures came in at $25.0 million (Q2 2026), $11.0 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Nomad Power Solutions | 49.59 Mn | 49.59 Mn | - | 24.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.99 Mn |
| Dec 31, 2025 | 10.96 Mn |
| Sep 30, 2025 | 4.91 Mn |
| Jun 30, 2025 | 651,456.00 |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 827,219.00 |
| Sep 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 2.25 Mn |
| Mar 31, 2024 | 3.13 Mn |
| Dec 31, 2023 | 3.99 Mn |
| Sep 30, 2023 | 4.92 Mn |
| Jun 30, 2023 | 2.69 Mn |
| Mar 31, 2023 | 4.08 Mn |
| Dec 31, 2022 | 5.17 Mn |
| Sep 30, 2022 | 6.41 Mn |
| Jun 30, 2022 | 7.49 Mn |
| Mar 31, 2022 | 3.47 Mn |
| Dec 31, 2021 | 4.79 Mn |
| Sep 30, 2021 | 6.07 Mn |
| Jun 30, 2021 | 6.87 Mn |